Fast Market Research

New Report Available: Age Related Macular Degeneration - Pipeline Review, H1 2014

Fast Market Research recommends "Age Related Macular Degeneration - Pipeline Review, H1 2014" from Global Markets Direct, now available

 
Repost This

Boston, MA -- (SBWIRE) -- 04/11/2014 -- Global Markets Direct's, 'Age Related Macular Degeneration - Pipeline Review, H1 2014', provides an overview of the Age Related Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned in this Report: Alcon, Inc., Genzyme Corporation, F. Hoffmann-La Roche Ltd., Allergan, Inc., Shionogi & Co., Ltd., GlaxoSmithKline plc, Dainippon Sumitomo Pharma Co., Ltd., RetinaPharma Technologies, Inc., Jeil Pharmaceutical Co., Ltd., Merz Pharma GmbH & Co. KgaA, iCo Therapeutics Inc., Mesoblast Limited, BioDiem Ltd, ReGenX Biosciences, LLC, OXiGENE, Inc., NeoStem, Inc., Progen Pharmaceuticals Limited, Handok Inc., HanAll Biopharma Co., Ltd., e-Therapeutics plc, R-Tech Ueno, Ltd., Paloma Pharmaceuticals, Inc., Digna Biotech, S.L., StemCells, Inc., Ora Bio Ltd., Foamix Ltd., Acucela Inc., BioMAS Ltd., Neovacs SA, Wellstat Ophthalmics Corporation, OcuCure Therapeutics, Inc., Gene Signal International SA, Promedior, Inc., Orphagen Pharmaceuticals, Inc., Grupo Ferrer Internacional, S.A., Intellect Neurosciences, Inc., FirstString Research, Inc., Stemedica Cell Technologies, Inc., Cellceutix Corporation, Sirnaomics, Inc., Resolvyx Pharmaceuticals, Inc, TRACON Pharmaceuticals, Inc., AngioGenex, Inc., SelectX Pharmaceuticals, Inc., California Stem Cell, Inc., Neumedicines Inc., Varinel, Inc., Aprogen, Inc., Alkeus Pharmaceuticals, Inc., X-BODY BioSciences, Inc., Clanotech AB, Valens Therapeutics, Inc., Allinky Biopharma, Neuroptis Biotech, AbbVie Inc., AlphaMab Co., Ltd, Huabo Biopharm Co., Ltd.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Age Related Macular Degeneration Global Clinical Trials Review, H1, 2014
- Age Related Macular Degeneration - Pipeline Review, H1 2013
- Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2013
- Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2013
- Glaucoma - Pipeline Review, H1 2014
- AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014
- Macular Degeneration - Pipeline Review, H2 2013
- Parkinson's Disease - Pipeline Review, H1 2014
- Alzheimer's Disease - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014